Already a Bloomberg.com user?
Sign in with the same account.
Jan. 26 (Bloomberg) -- Sanofi said it’s starting the last of three stages of human testing for its experimental pill for Gaucher disease, a rare genetic illness.
Results from the second phase of testing for the pill, called eliglustat, will be presented next month, said Marisol Peron, a Sanofi spokeswoman, in an interview.
To contact the reporter on this story: Trista Kelley in London at email@example.com
To contact the editor responsible for this story: Kristen Hallam at firstname.lastname@example.org